ArticleScientific reports2025
Melissa officinalis essential oil modulates oxidative balance, cholinergic activity, and cognitive performance in a scopolamine-induced zebrafish model: implications for neuroprotective strategies in cognitive disorders.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic Administration of Carvone-RichPlants (Basel, Switzerland) · 2026Article
- Unlocking the Power of Plant-Derived Natural Products: Therapeutic Benefits for Cognitive Health and Neuropsychiatric Symptoms in Dementia-Related Diseases.Plants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melissa officinalis essential oil (MEO) possesses documented neuroprotective, antioxidant, and anxiolytic properties. This study investigated the effects of MEO (150 and 300 µL/L) in a scopolamine (SCO, 100 µM)-induced zebrafish model of cognitive impairment. Cognitive performance was assessed using the Y-maze and novel object recognition (NOR) tests for spatial and recognition memory. At the same time, anxiety-like behaviors were evaluated via the novel tank diving test (NTT) and the novel approach test (NAT). MEO was administered daily for 21 days, whereas SCO and the reference drug galantamine (GAL, 1 mg/L) were administered acutely before behavioral testing. MEO significantly ameliorated SCO-induced cognitive deficits, reduced anxiety-like behaviors, inhibited brain acetylcholinesterase (AChE) activity, and mitigated oxidative stress markers. In silico ADMET predictions for MEO's major constituents (citral, β-caryophyllene, limonene, and α-pinene) indicated high gastrointestinal absorption, blood-brain barrier permeability, and favorable safety profiles, with no predicted mutagenic or hepatotoxic effects. Collectively, these findings support the neuroprotective and anxiolytic potential of MEO in a zebrafish model of cognitive dysfunction and suggest its promise as a candidate for further investigation in neurodegenerative disease research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.